|
MRPL50 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.36040001486037E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.39770000018302E-07 |
| Normal-vs-Stage2 |
7.71880000000058E-05 |
| Normal-vs-Stage3 |
1.43130000074265E-08 |
| Normal-vs-Stage4 |
1.00380037615366E-10 |
| Stage1-vs-Stage2 |
4.793000E-01 |
| Stage1-vs-Stage3 |
2.834000E-02 |
| Stage1-vs-Stage4 |
5.76959999999405E-05 |
| Stage2-vs-Stage3 |
4.431600E-01 |
| Stage2-vs-Stage4 |
1.887900E-02 |
| Stage3-vs-Stage4 |
4.471700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.57780002583297E-09 |
| Normal-vs-AfricanAmerican |
2.189100E-04 |
| Normal-vs-Asian |
3.55350000003085E-06 |
| Caucasian-vs-AfricanAmerican |
5.057600E-01 |
| Caucasian-vs-Asian |
7.682400E-01 |
| AfricanAmerican-vs-Asian |
6.889800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.42950004558651E-09 |
| Normal-vs-Female |
1.90009999956331E-08 |
| Male-vs-Female |
1.444800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.46429999997788E-06 |
| Normal-vs-Age(41-60Yrs) |
2.41099995523797E-09 |
| Normal-vs-Age(61-80Yrs) |
1.32049999823636E-08 |
| Normal-vs-Age(81-100Yrs) |
2.320800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.371900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.060600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.431190E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.811400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.783800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.978000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.346200E-02 |
| Classical-VS-Follicular |
1.089020E-01 |
| Classical-VS-Other |
6.089000E-01 |
| Classical-VS-Normal |
8.78060000264469E-08 |
| Tall-VS-Follicular |
6.607800E-01 |
| Tall-VS-Other |
6.939800E-01 |
| Tall-VS-Normal |
3.28130000004645E-06 |
| Follicular-VS-Other |
9.231800E-01 |
| Follicular-VS-Normal |
7.50280000016978E-07 |
| Other-VS-Normal |
2.233800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.05610000136858E-08 |
| Normal-vs-N1 |
9.10390000052885E-07 |
| N0-vs-N1 |
3.883800E-01 |
|
|
